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Abstract
Studies of human NK cells and their role in tumor suppression have largely been restricted to in vitro experiments which lack
the complexity of whole organisms, or mouse models which differ significantly from humans. In this study we showed that,
in contrast to C57BL/6 Rag2
2/2/cc
2/2 and NOD/Scid mice, newborn BALB/c Rag2
2/2/cc
2/2 mice can support the
development of human NK cells and CD56+ T cells after intrahepatic injection with hematopoietic stem cells. The human
CD56
+ cells in BALB/c Rag2
2/2/cc
2/2 mice were able to produce IFN-c in response to human IL-15 and polyI:C. NK cells from
reconstituted Rag2
2/2/cc
2/2 mice were also able to kill and inhibit the growth of K562 cells in vitro and were able to
produce IFN-c in response to stimulation with K562 cells. In vivo, reconstituted Rag2
2/2/cc
2/2 mice had higher survival
rates after K562 challenge compared to non-reconstituted Rag2
2/2/cc
2/2 mice and were able to control tumor burden in
various organs. Reconstituted Rag2
2/2/cc
2/2 mice represent a model in which functional human NK and CD56+ T cells can
develop from stem cells and can thus be used to study human disease in a more clinically relevant environment.
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Introduction
Mouse models are used extensively for the study of human
disease in many fields including cancer. Although mice have
provided valuable insights into disease initiation, progression and
therapy, they do not accurately represent human immune
responses and results obtained in mice are therefore difficult to
extrapolate to humans. Although it is clear that humans cannot be
used as subjects in many experiments, a model which better
represents the human response would be a logical step forward. A
humanized mouse model represents a valuable means of assessing
human immune responses to diseases such as cancer.
Several immunodeficient mouse strains have been used to engraft
human stem cells. NOD/Scid mice have been shown to consistently
support human stem cell engraftment and have been used
extensively [1–3]. However, NOD/Scid mice suffer from a high
rate of thymomas, the presence of residual NK cells and
spontaneous development of murine T and B cells. In addition,
they do not develop human T or NK cells without further
manipulation[4–6]. It is therefore difficult to use these micein long-
term immunological studies. Improved models which lack the
problems of the NOD/Scid strain and support full differentiation of
human stem cells have since been developed. In one model, the
NOD/Scid strainwasmodified bybackcrossingitwiththecommon
cytokine receptor gamma chain knockout mouse (cc
2/2) [7] and in
a similar model, the cc
2/2 mouse was genetically crossed with the
recombinase activating gene 2 knockout (Rag2
2/2) mouse [8].
Rag2
2/2/cc
2/2 mice are alymphoid, lacking B cells, T cells and
NK cells and are excellent recipients for human cell engraftment. It
is interesting to note however, that engraftment in these mice is
dependent on both the age of the mice at the time of stem cell
delivery and the background strain of the mice as only newborn
Rag2
2/2/cc
2/2 mice on a BALB/c background appear to support
engraftment [9]. These restrictions do not seem to apply to mice
with the NOD/Scid mutations which support engraftment at any
age, although differentiation of T and NK cells in these mice does
not occur without further manipulation. Most studies to date have
focused on generating human adaptive immune responses in
humanized mouse models and several successful studies have been
reported. Human innate immune responses have also been
examined in this model, although to a lesser extent. Functional
dendritic cells have been shown to develop in the reconstituted
BALB/c Rag2
2/2/cc
2/2 mice [10]. Human NK cells have also
been shown to develop [11] and in a recent study, have been shown
to respond to exogenously administered human IL-15 which
improved their development in vivo [12].
Theinnateimmunesystemisthe firstline ofdefenseandiscrucial
for containing and eliminating a wide range of tumor cells or
microbial pathogens without prior exposure. Both NK and non-
MHC restricted NKT cells have been shown to have innate anti-
tumor activity. For example, in patients with acute myeloid
leukemia (AML) undergoing allogenic stem cell transplantation,
alloreactive NK cells have been shown to have antileukemic effects
which resulted in improved survival of the patients [13].
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potential rolein treatment of AML when adoptively transferred into
patients [14]. NKT cells have been shown to have non-MHC
restricted innate anti-tumor activities similar to those of NK cells
however these innate functions have only been examined in vitro
[15,16]. A possibleroleforNK/NKT cellsinpreventingthenatural
development of cancer has been shown in a cohort study in which
low levels of cytotoxic activity of peripheral blood lymphocytes was
linked to an increased risk of cancer [17]. Studies have shown that
NK and NKT cell precursors exist within the human CD34
+
hematopoietic cell population in umbilical cord blood and can
differentiate into mature NK cells in vitro in the presence of IL-15
and cytokines such as flt3 ligand or stem cell factor [18–21].
Our understanding of human NK and NKT cell function has
primarily been based on in vitro analyses, and in vivo models to study
human NK/NKT cells are lacking. Valuable information has been
gained fromstudyingmurine NK/NKT cellsand ithasbeenshown
thatbothNKandNKTcellshavepotentanti-tumoractivitiesin vivo
[22–25]. However, while there are similarities between murine and
human NK cells, there are also many differences which make it
difficult to implement results obtained from murine studies into
humans [26]. In an attempt to examine human NK cell function in
vivo, several studies have used immunodeficient mice into which
human tumor cells or pre-differentiated and activated human NK
cells were injected. These studies have shown that NK cells can
inhibit tumor growth and that the absence of NK cells enhances
tumorigenicity [27,28]. Although mouse models have the capacity
to support NK/NKT cell activity and tumor growth, they do not
develop NK/NKT cells from in vivo precursors and therefore may
not accurately represent natural human responses. In this study, we
show that human CD56+ NK and T cells develop in vivo from
hematopoietic stem cells in BALB/c Rag2
2/2/cc
2/2 mice injected
as newborns but not C57BL/6 Rag2
2/2/cc
2/2 mice or NOD/
Scid mice. The human CD56+ cells are able to produce IFN-c in
response to polyI:C and IL-15 and cells from reconstituted mice are
able to respond to the human NK-sensitive K562 erythroleukemia
cell line by producing IFN-c and inhibiting tumor growth both in
vitro and in vivo.
Materials and Methods
Ethics
All animal experiments were approved by the Animal Research
Ethic Board (AREB) of McMaster University. Use of human cord
blood was approved by the Research Ethic Board (REB) of
McMaster University. Human cord blood samples were obtained
with parent written informed consent.
Mice
NOD/Scid mice were purchased from The Jackson Lab (Bar
Harbor, ME). C57BL/6 Rag2
2/2/cc
2/2 mice were purchased
from Taconic (Germantown, NY). BALB/c Rag2
2/2/cc
2/2
mice were generously provided by M. Ito (Central Institute for
Experimental Animals, Kawasaki, Japan). All mice were bred and
maintained under specific pathogen-free conditions at the
McMaster University Medical Center. Mouse colonies were
maintained on a 12 h light/12 h dark light cycle.
Transplantation of Human Cord Blood-Derived Stem
Cells into Mice
Human cord blood samples were obtained with parent written
informed consent. (Department of Labour and Delivery, McMas-
ter University Medical Center, Hamilton, Ontario). Mononuclear
cells were enriched from whole blood using HetaSep (Stem Cell
Technologies, Vancouver, British Columbia). CD34
+ cells were
enriched by removing lineage committed cells using a cocktail of
antibodies with the RosetteSep system according to the manufac-
turer’s instructions (Stem Cell Technologies, Vancouver, BC).
Injected cells were 70–80% CD34
+ and no lineage positive cells
remained. Samples were frozen immediately until use.
Mice were injected either at 6–8 weeks of age or on the day of
birth. Adult NOD/Scid mice were irradiated with 3.5 Gy and
adult Rag2
2/2/cc
2/2 mice were irradiated with 5–6 Gy. Both
strains were injected with 1–3610
6 CD34-enriched cells into the
tail vein. Newborn mice were irradiated twice in a 3–4 hour
interval. Newborn NOD/Scid mice received 1.561.5 Gy and
newborn Rag2
2/2/cc
2/2 mice recieved 363 Gy. After the
second dose of irradiation, newborn mice were injected intrahe-
patically with approximately 1–2610
6 CD34-enriched cells in
30 ul PBS using a 30-guage needle. Control mice were irradiated
using the same protocol but did not receive any human cells. Mice
were weaned at 3 weeks of age.
Analysis of Human Cell Engraftment
At 12–20 weeks post-transplantation, mice were euthanized and
examined for the presence human lymphocytes. Single cell
suspensions were made from bone marrow, spleen, lymph nodes,
thymus and blood. Spleens, lymph nodes and thymus were passed
through a 40 um filter and red blood cells were removed with
ACK lysis buffer.
Cells were stained for FACS with antibodies against human
CD45 PE (HI30), CD56 PE (B159), (NCAM16.2), CD3 FITC
(HIT3a), CD16 PE-Cy5 (3G8) (BD Pharmingen, San Diego,
California), CD94 APC (DX22), KIR3DL1 Alexa Fluor 700
(DX9), NKp30 APC (P30-15), NKp44 PE (P44-8), NKG2D PE
(1D11), KIR2DL2/L3 FITC (DX27) (Biolegend, San Diego, CA)
and NKp46 FITC (195314) (R&D Systems, Minneapolis, MN).
Flow cytometric data was collected using a FACScan, LSR II or
FACS Canto (Becton Dickinson) and was analyzed using FlowJo
software. For data collected using the FACScan, compensation
was done manually using single-stained cells. For data collected
using the LSR II and FACS Canto, compensation was done with
FACS Diva software using single-stained compensation beads.
NK Cell Stimulation and IFN-c measurement
Naı ¨ve reconstituted mice were euthanized and spleen and
mesenteric lymph nodes were removed. Single cell suspensions
from these organs were incubated with K562 cells for 72 hours. In
a separate experiment, 5610
5 spleen and lymph node cells were
cultured with human IL-2 (400 U/ml; R&D Systems, Minneapo-
lis, MN) and either recombinant human IL-15 (200 ng/ml; R&D
Systems, Minneapolis, MN) or polyI:C (25 mg/ml, Sigma,
Oakville, ON) for 72 hours. IFN-c production by NK cells was
measured in both experiments by ELISA and/or by FACS using
CD56 surface staining and intracellular cytokine staining. For
intracellular cytokine staining, GolgiPlug (1 ul/ml; BD Bioscienc-
es, San Diego, CA) was added to the cultures for the last 6 hours.
CD107a degranulation assay
Cells from the spleen and thymus of reconstituted mice were
used as effectors in a CD107a assay. Cells were incubated with
K562 target cells or left unstimulated to detect spontaneous
degranulation. Effectors and targets were plated at an E:T ratio of
2:1 and incubated for 4 hours at 37uC and 5% CO2. Anti-human
CD107a mAb FITC (H4A3) (Biolegend, San Diego, CA) was
added to each well at the start of the incubation (20 ul/well). After
1 hour, 4 ul of BD GolgiStop (BD Biosciences, San Diego, CA)
was added for every 6 ml of cell suspension. After the incubation,
Human NK Cells in Mice
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Pharmingen, San Diego, CA), CD3 PerCP-Cy5.5 (HIT3a) and
CD56 PE-Cy7 (HCD56) (Biolegend, San Diego, CA) for flow
cytometric analysis. Data was collected using a FACS Canto
(Becton Dickinson) and analyzed using FlowJo software.
In vitro K562 cell growth inhibition measurement
Spleen and lymph node cells from naı ¨ve reconstituted
Rag2
2/2/cc
2/2 mice and non-reconstituted Rag2
2/2/cc
2/2
and BALB/c controls were isolated and cultured in 10% RPMI
with K562 cells at a 50:1 effector to target ratio. After 60 hours,
human IL-2 (400 U/ml) and IL-15 (100 ng/ml) were added to the
cultures for an additional 10 hours. The number of surviving cells
was determined by adding 1610
5 FITC-labeled beads to each
tube and counting the number of K562 cells in the culture by
FACS. The following equation was used: number of added beads
(1610
5)6number of counted targets (K562)/number of counted
beads. Since the cells were cultured for 72 hours, specific growth
inhibition of K562 cells was measured instead of specific lysis.
Calculation of % growth inhibition was adapted from a
recent study [29] and was calculated as (number of surviving
K562spontaneous–number of surviving targetsexperimental)/(number of
surviving targetsspontaneous)6100.
K562 Tumour Injection and Monitoring
At 10–12 weeks post-transplantation, 5610
5 K562 cells were
injected into the tail vein of mice. After injection mice were
weighed and monitored daily for sickness and tumor formation.
Mice were monitored for up to 90 days and were euthanized when
approximately 20% of total body weight was lost or when tumors
were large enough to impair eating or walking. In a separate
experiment, reconstituted and non-reconstituted mice were
euthanized 40 days after challenge and bone marrow, spleen,
liver and blood were removed. Single cell suspensions were stained
for FACS with glyA PE (GA-R2) (BD biosciences) to detect
tumour cells.
CD56 depletion
Anti-human CD56 IgM antibodies were prepared from the
supernatant of HNK-1 cells (ATCC) Cells were cultured
according to ATCC recommendation for propagation and then
cultured in serum free media for antibody production. Cells were
pelleted and supernatants were then centrifuged to remove any cell
debris. The IgM in the supernatant was then precipitated with
saturated ammonium sulfate to reach a 40% solution and then
stored at 4uC overnight. The protein precipitate was then
centrifuged and dialyzed in several changes of PBS. The purity
Figure 1. Analysis of reconstitution in immunodeficient mice. Newborn NOD/Scid, C57BL/6 Rag2
2/2/cc
2/2 and BALB/c Rag2
2/2/cc
2/2 mice
were examined 12 weeks after injection with human cord blood derived hematopoietic stem cells. (A) Bone marrow, spleen, lymph nodes and
thymus were examined by FACS for the presence of human CD45
+ cells. For bone marrow and spleen n=20 mice, for lymph nodes n=10 mice, for
thymus n=5 mice. Lightweight line represents unreconstituted BALB/c Rag2
2/2/cc
2/2 mouse, dark line represents reconstituted BALB/c Rag2
2/2/
cc
2/2 mouse. Isotype controls were also negative (not shown) (B) Summary graph of human CD45 reconstitution in mouse strains and tissues The y
axis, in figure 1b, is of the irrelevant channel.
doi:10.1371/journal.pone.0008379.g001
Human NK Cells in Mice
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was determined by both ELISA and Bradford assay. The purified
anti-CD56 antibodies were injected into reconstituted and non-
reconstituted mice (0.2 mg/mouse) 2 days before administration of
K562 cells and every 2–3 days after K562 cell injection. Delivery
of K562 cells and monitoring of mice was performed as described
in the previous section. The anti-CD56 antibody delivery was
maintained until endpoint when the mice succumbed to the tumor
burden. CD56-depleted mice were examined for the presence of
CD56
+ cells by FACS after the first 2 antibody injections and at
endpoint to ensure the depletion was maintained. CD56 staining
was performed using 2 different antibody clones. In addition, cells
were also stained for CD16.
Statistics
Survival data was analyzed using the chi-squared test.
Differences in IFN-c levels, growth inhibition and % dead cells
between reconstituted and non-reconstituted mice as well as
differences in degranulation between co-culture with and without
K562 cells were evaluated using Mann-Whitney Rank Sum test.
Results
Reconstitution and development of CD56
+ NK and T cells
in immunodeficient mouse strains
At 12–14 weeks post-transplantation, single cell suspensions
from bone marrow, spleens and lymph nodes were examined for
the presence of human lymphocytes. Human CD45
+ cells were
observed in the bone marrow and spleen of all NOD/Scid and
BALB/c Rag2
2/2/cc
2/2 mice that had received grafts as
newborns (fig. 1A, B). Similar levels of reconstitution were
detected in NOD/Scid mice that received grafts as adults but no
CD45
+ cells were present in adult BALB/c Rag2
2/2/cc
2/2
recipient mice (data not shown). No reconstitution was detected in
newborn or adult C57BL/6 Rag2
2/2/cc
2/2 recipient mice.
Only BALB/c Rag2
2/2/cc
2/2 mice that received grafts as
newborns developed detectable lymph nodes which were almost
entirely made up of human CD45
+ cells (fig. 1A). As expected,
none of the non-reconstituted mice developed lymph nodes.
Since we were interested in the innate immune response, we
next determined whether human CD56
+ cells developed in the
reconstituted mice. Neither newborn nor adult NOD/Scid
recipient mice developed any CD56
+ cells in the spleen (fig. 2A).
BALB/c Rag2
2/2/cc
2/2 mice developed CD56
+ cells in the
spleen, lymph nodes and thymus which were present at variable
levels in each mouse. We detected between 0.5% and 8% human
CD56
+ cells in the spleen, between 8% and 40% in the lymph
nodes and between 0.5% and 7% in the thymus (fig. 2A, B). These
results indicate that only the newborn BALB/c Rag2
2/2/cc
2/2
model has the potential to be used for innate immune and NK cell
experiments and is therefore the only strain used in the remainder
of this study.
Distribution and characterization of human CD56
+ cells
in BALB/c Rag2
2/2/cc
2/2 mice
We next examined the tissue distribution of the CD56
+ cells in
reconstituted mice as well as the presence of CD3 and CD16 on
these cells. As shown in Figure 2, no CD56
+ cells were detected in
the bone marrow. As mentioned above, reconstitution of CD56
+
cells was quite variable in the spleen however, the majority of the
CD56 positive cells that developed were negative for both CD16
and CD3 (fig. 3). Variability in the proportion of CD56
+ cells was
also observed in the mesenteric lymph nodes however, a much
larger percentage of the cells in the lymph node expressed CD56
(fig. 2). Of the CD56
+ cells, most expressed CD16 however there
was a population that was also CD16
2. In addition, CD3 was
detected on the majority of CD56
+ cells in the lymph nodes (fig. 3)
indicating that many of the cells displayed an NK and T cell
phenotype. In the blood, cells were CD56
+CD16
+ and
CD56
+CD3
2 indicating a lack of T cells and in the thymus
CD56
+ cells were either CD16 positive or negative (fig. 3). Each
Figure 2. Analysis of NK cell reconstitution in immunodeficient
mice. Newborn NOD/Scid, C57BL/6 Rag2
2/2/cc
2/2 and BALB/c
Rag2
2/2/cc
2/2 mice were examined 12 weeks after injection with
human cord blood derived hematopoietic stem cells. For bone marrow
and spleen n=20 mice, for lymph nodes n=10 mice, for thymus n=5
mice. LightweightlinerepresentsunreconstitutedBALB/cRag2
2/2/cc
2/2
mouse, dark line represents reconstituted BALB/c Rag2
2/2/cc
2/2 mouse.
Isotype controls were also negative (not shown) (A) Spleen, lymph nodes
and thymus were also examined for the presence of human CD56
+ cells.
(B) Summary of CD45+CD56+ cells in tissues of BALB/c Rag2
2/2/cc
2/2
mice. For all tissues n=8 mice.
doi:10.1371/journal.pone.0008379.g002
Human NK Cells in Mice
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isotype controls were also included (Figure S1).
In order to further characterize the human NK cells in
reconstituted mice, CD56
+CD3
2 cells were stained with several
NK cell inhibitory and activation markers (fig. 4). Figure 3 shows
staining on cells from the thymus as this tissue had the highest
number of CD56
+CD3
+ cells. Expression levels of the natural
cytotoxicity receptors (NCR) NKp46 and NKp30 as well as KIRs
was variable between mice however, expression was consistently
positive indicating a mature phenotype. Approximately 20% of
NK cells expressed the activating receptor NKG2D and a similar
percentage expressed the inhibitory receptor CD94. NKp44 was
present on a small population of NK cells (fig. 4).
Presence of functional human CD56
+ NK and T cells in
BALB/c Rag2
2/2/cc
2/2 mice
After establishing that human CD56
+ NK and T cells can
develop in newborn BALB/c Rag2
2/2/cc
2/2 mice, we next
determined whether the cells are functional. Spleen and lymph
node cells from reconstituted mice and non-reconstituted
Rag2
2/2/cc
2/2 or BALB/c control mice were stimulated with
human IL-2 and either IL-15 or polyI:C. After 72 hours, human
IFN-c was detected in all of the reconstituted culture supernatants
by ELISA (fig. 5A). In order to confirm that the IFN-c was being
produced by human CD56
+ cells, intracellular cytokine staining
(ICCS) was performed. In the lymph nodes, up to 80% of the
CD56
+ cells from reconstituted mice produced IFN-c in response
to human IL-15/IL-2 and up to 66% of CD56
+ cells produced
IFN-c in response to polyI:C (fig. 5B). To further confirm this
observation, we determined that the majority of the IFN-c positive
cells in the cultures were CD56
+ (fig. 5C). These observations
further indicate that in vivo, early IFN- c is likely produced by
CD56
+ cells.
Ability of human cells to kill and inhibit K562 cell growth
in vitro
After determining that the human CD56
+ cells from reconsti-
tuted Rag2
2/2/cc
2/2 mice could produce IFN-c, we examined
Figure 3. Development of NK and NKT cells in reconstituted BALB/c Rag2
2/2/cc
2/2 mice. Cells from bone marrow, spleen, mesenteric
lymph nodes, blood and thymus of reconstituted mice were collected 12 weeks after injection of human hematopoietic stem cells and were stained
for human CD56 and either CD16 or CD3. (A) Represenative FACS plots. All plots were gated on the lymphocyte population. All the gates in this figure
were set based on isotype controls which were run at the same day with the same samples. Isotype controls were negative for all antibodies
(supplemental data, figure 1). (B) Summary of staining from each tissue. Bars represent the mean percentage of CD56+ cells that are either CD3+ or
CD16+ (6SEM). Data is representative of 4 mice.
doi:10.1371/journal.pone.0008379.g003
Human NK Cells in Mice
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their ability to kill or inhibit the growth of K562 cells.
A 4-hour CD107a degranulation assay was performed using
thymus cells from reconstituted mice cultured with NK-sensitive
K562 cells. There was a significant difference in the percentage of
NK cells that expressed CD107a after culture with or without
K562 cells (fig. 6A, p,0.005). CD107a expression by human
CD56
+CD3
2 cells was detected in approximately 20% of cells that
were cultured with K562 cells compared to just 1% of cells
cultured in the absence of K562 cells (fig. 6A), indicating that
human NK cell are able to degranulate in response to K562 target
cells. No increase in CD107a expression was observed on
CD56
+CD3
+ cells (data not shown).
In a long-term in vitro experiment, spleen and lymph node cells
from reconstituted and non-reconstituted mice were isolated and
cultured with K562 cells for 72 hours. The total number of K562
cells in the culture after this time was measured by FACS and
compared between groups. K562 cells cultured alone were used as
an additional control. As shown in figure 6B, the number of K562
cells cultured in the presence of spleen cells from reconstituted
mice was significantly less than that measured from cultures with
cells from non-reconstituted mice or no exogenous cells (p,0.05).
A decrease in the number of surviving K562 cells was also
observed in the lymph node cultures from reconstituted mice
although the results were not as dramatic as seen in the spleen
(data not shown). In addition, compared to cultures with non-
reconstituted cells, approximately four times more K562 cells were
dead in the reconstituted spleen cell cultures (fig. 6C). These results
indicate that the human cells from reconstituted mice have a
significant effect on the growth of K562 cells in vitro.
We then quantified the effect of human CD56
+ cells on K562
cells, by calculating the percentage of K562 growth inhibition
when cultured with spleen cells compared to uninhibited growth.
As shown in figure 5D, spleen cells from non-reconstituted mice
inhibited growth by only 47% over 72 hours whereas growth
inhibition by spleen cells from reconstituted mice was significantly
higher at an average of 80% with cells from some mice causing up
to 96% growth inhibition (p,0.05). It is thus clear that the human
CD56
+ cells from reconstituted mice can almost completely block
the expansion of K562 cells in vitro.
In order to further demonstrate that the human CD56
+ cells are
active in response to K562 cells, human IFN-c production by
CD56
+ cells was measured by ICCS. Lymph node cells from
reconstituted mice were isolated and cultured with K562 cells for
72 hours. Cells were then collected and stained for the expression
of human CD56 and IFN-c. Almost all of the CD56
+ cells were
active in response to the K562 cells and expressed IFN-c.I n
addition, the IFN-c was being produced exclusively by CD56
+
cells as over 99% of the IFN-c
+ cells in the culture were CD56
+
(data not shown).
Survival of reconstituted Rag2
2/2/cc
2/2 mice after K562
cell injection
After determining that the human NK cells from reconstituted
Rag2
2/2/cc
2/2 mice could inhibit growth and produce IFN-c in
response to K562 cells in vitro, we examined whether these cells
could respond to tumor cells in vivo. In two separate experiments, 9
reconstituted and 6 non-reconstituted Rag2
2/2/cc
2/2 mice were
injected i.v. with K562 cells and were monitored for loss of body
weight and tumor formation. Both groups were irradiated as
newborns. As shown in figure 7, it is clear that the reconstituted
mice were able to survive the tumor challenge significantly better
than the non-reconstituted mice (p,.0001). Further demonstrating
their ability to defend against tumor challenge, reconstituted mice
showed an overall gain in total body weight whereas non-
reconstituted Rag2
2/2/cc
2/2 mice lost approximately 20% of
Figure 4. Expression of human NK cell markers on cells from reconstituted BALB/c Rag2
2/2/cc
2/2 mice. Cells from the thymus of
reconstituted mice were isolated and stained for FACS analysis. Cells were stained with antibodies against NKp46, NKp30, NKp44, NKG2D, KIR3DL1,
KIR2DL2/L3 and CD94 (dark line). All plots are gated on CD45
+CD56
+CD3
2 cells. Light gray line represents staining with isotype control antibody.
Figures are representative of 4 mice.
doi:10.1371/journal.pone.0008379.g004
Human NK Cells in Mice
PLoS ONE | www.plosone.org 6 December 2009 | Volume 4 | Issue 12 | e8379their total body weight (fig. 7). Reconstituted and non-reconsti-
tuted mice that were not challenged with K562 cells both survived
and gained body weight equally up to the 90 day experimental
endpoint (data not shown). The majority of the reconstituted mice
did not develop any detectable tumors and lived beyond the 90
day experimental endpoint (Figure S2). Those that did develop
tumors were not euthanized until 68 days after tumor challenge
compared to the non-reconstituted mice which developed large
tumors and were euthanized between 45 and 55 days after K562
cell injection. These results show that human CD56
+ cells in
reconstituted mice are able to respond to K562 tumor cell
challenge and likely contribute to the protective immune
responses.
Tumor burden and IFN-c production in K562-challenged
Rag2
2/2/cc
2/2 mice
In order to determine the extent to which human cells were able
to inhibit K562 cell growth in vivo, tumor burden was measured in
both reconstituted and non-reconstituted Rag2
2/2/cc
2/2 mice.
At 40 days after K562 cell injection, reconstituted and non-
reconstituted mice were euthanized and analyzed for the presence
of tumor cells. Mice that reached endpoint developed large solid
tumors in the abdomen, primarily encompassing the kidneys and
liver as well as in the jaw. Circulating tumor cells were also
detected. In order to determine the significance of the tumor
burden in the reconstituted and non-reconstituted mice, single cell
suspensions of bone marrow, spleen, liver and blood were
Figure 5. Human IFN-c production by NK cells from reconstituted BALB/c Rag2
2/2/cc
2/2 mice. Mesenteric lymph node or spleen cells
were stimulated with human IL-15/IL-2 or polyI:C/IL-2 for 48 hours. (A) Human IFN-c was detected in the supernatants of both lymph node (top) and
spleen (bottom) cultures by ELISA. n=4 mice for each tissue and treatment (B) Cells from lymph node cultures were stained for FACS with human
CD56 and IFN-c. Cells were gated on CD56
+ and analyzed for production of IFN-c. (C) In a separate analysis, lymph node cells were gated on IFN-c
+
and stained with anti-human CD56. (D) Lymph node cells from Balb/c mice were stimulated as above and stained with CD56 and IFN-c as controls to
ensure no non-specific staining occurred. Figures B–C are representative of 4 mice. Figure D is representative of 5 mice.
doi:10.1371/journal.pone.0008379.g005
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expressed by K562 cells. All non-reconstituted organs examined
contained significantly higher percentages of K562 cells than
organs from reconstituted mice. As shown in figure 8, most K562
cells engrafted into the liver however, K562 cells were also
detected in the bone marrow, spleen and circulation. Cultured
K562 cells before injection stained positive for glycophorin A as
did cells from solid tumors removed from the abdomen of non-
reconstituted mice (not shown). Reconstituted mice that survived
up to 90 days after K562 cell injection were able to completely
clear the tumor cells as none were detected by FACS staining
(Figure S2). This is a clear illustration of the degree of protection
offered by the human cells in reconstituted mice. In addition,
spleen cells from reconstituted mice that were challenged with
K562 produced 12-fold more human IFN-c (as measure by
ELISA) than spleen cells from naı ¨ve reconstituted mice when
stimulated for 48 hours with polyI:C and 3-fold more when
stimulated with IL-15 (data not shown).
CD56 depletion and K562 tumor challenge
In order to confirm the role of CD56
+ cells in tumor protection,
reconstituted and non-reconstituted mice were injected with anti-
CD56 antibodies to deplete NK cells. Mice were then injected i.v.
with 5610
5 K562 cells and monitored for survival. As shown in
figure 9A, reconstituted mice were completely depleted of CD56
+
cells both before K562 cell injection and at endpoint indicating
that the depletion was maintained throughout the experiment.
Reconstituted mice that were depleted of CD56
+ cells had survival
rates equal to that of non-reconstituted mice (fig. 9B) and the body
weight of all mice dropped equally (fig. 9C) indicating that there
was no difference in protection between the reconstituted CD56-
depleted and the non-reconstituted mice. Reconstituted mice that
were injected with K562 cells but not treated with anti-CD56 all
survived until the experimental endpoint at day 100 post K562
innoculation (n=4; data not shown). These results indicate that
human CD56
+ cells play a significant role in the protection that
was observed in reconstituted non-CD56-depleted mice (fig. 7).
Discussion
NK cells are a vital component of the innate immune system
and have long been implicated in the detection and elimination of
tumor cells [30]. In this study, we examined whether immuno-
deficient mice could support the development of human NK and
NKT like (CD56
+/CD3
+) cells in various tissues and whether
these cells could effectively target human K562 tumor cells.
We examined several immunodeficient mouse models and
found, as previously reported, that while engraftment in NOD/
Scid mice is not dependent on age at the time of stem cell delivery,
Rag2
2/2/cc
2/2 mice are only able to support high levels of
engraftment when stem cells are delivered at birth [9,31]. In
addition, the background strain of the Rag2
2/2/cc
2/2 mice
appears to play a crucial role in graft acceptance as C57BL/6
Rag2
2/2/cc
2/2 mice (at any age) do not support engraftment
whereas newborn BALB/c Rag2
2/2/cc
2/2 mice are able to
support full differentiation of human immune cells [11,16].
Figure 6. NK cell degranulation and inhibition of K562 cell growth by spleen cells. (A) K562 cells were cultured with thymus cells from
reconstituted mice for 4 hours. Cells were stained with CD56, CD3 and CD107a in order to measure degranulation of NK cells. Contour plots show
representative CD107a staining on CD56
+CD3
2 cells cultured with or without K562 cells. Bar graph shows significantly greater expression of CD107a
on cells cultured with K562 stimulation compared to cells cultured in the absence of K562 stimulation (p,0.005). n=4 mice (B–D) K562 cells were
cultured with spleen cells from reconstituted mice, non-reconstituted mice or alone for 72 hours and then harvested and stained for analysis by
FACS. (B) The total number of surviving K562 cells was determined as described in materials and methods. (C) The percentage of dead K562 cells in
the cultures was determined by staining with 7AAD. (D) % growth inhibition of K562 cells was calculated as described in materials and methods. For
all experiments in B–D, reconstituted n=3, non-reconstituted n=6. Bars represent mean6SEM. * indicates significant difference between the
reconstituted and non-reconstituted groups (p,0.05).
doi:10.1371/journal.pone.0008379.g006
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that differences in growth factors exist within the bone marrow
environment of the two strains which influence engraftment. It is
also possible that known differences in immune responses between
BALB/c and C56BL/6 mice could affect engraftment. The focus
of this study was on human NK cells and it was therefore crucial to
determine which mouse strain would best support NK cell
development. We have shown here that reconstituted NOD/Scid
mice, regardless of age, are devoid of human CD56
+ cells while
reconstituted newborn Rag2
2/2/cc
2/2 mice develop them in the
spleen, lymph nodes and thymus. The lack of CD56
+ cell
development in the NOD/Scid mice is likely due to interference
by residual murine NK cells which are not present in Rag2
2/2/
cc
2/2 mice. We therefore determined that the newborn BALB/c
Rag2
2/2/cc
2/2 mice were the most suitable model for examining
the role of human CD56
+ cells in innate tumor immunity.
It is well known that NK cells and possibly NKT cells play a
crucial role in the innate immune response. They are highly
responsive to a variety of cytokines including IL-2, IL-12 and IL-15
and following interaction of NK cell surface receptors with cognate
ligands, they mediate cytotoxicity via perforin/granzyme granule-
mediated exocytosis and produce several cytokines including IFN-c
[23,32]. Previous studies have shown that administration of
exogenous cytokines, such as IL-15, is required for the development
of mature NK cells in vitro and in immunodeficient mice [20,33–35].
A recent studyby Huntington et.al.,[12] examined therole of IL-15
in regulating the development of human NK cells in BALB/c
Rag2
2/2/cc
2/2 mice. They reconstituted the mice with CD34+
human fetal liver cells and showed that exogenous delivery of
human IL-15 plus IL-15 receptor agonists enhanced the develop-
ment, differentiation and proliferation of NK cells [12]. In the
present study, we have shown that CD56
+ NK and T cells develop
naturally in BALB/c Rag2
2/2/cc
2/2 mice reconstituted with
lineage-depleted human umbilical cord blood cells, without the
need for further manipulation. The levels of NK cells observed in
the present study were generally higher than those observed by
Huntington et.al. which may be due to differences in the source of
the humancells, the numberof cells delivered or the method used to
enrich hematopoietic stem cells. We have used negative selection
which results in the enrichment of CD34+ as well as other possible
HSCs. The distribution of the human CD56
+ cells in the mice was
interestingasCD56
+/CD3
+cellsweremainlydetectedinthe lymph
nodes of reconstituted mice and CD56
+/CD3
2 cells were detected
in all tissues except bone marrow. Further examination of
CD56
+CD3
2 NK cells revealed that several human NK markers
are expressed including the natural cytotoxicity receptors (NKp46,
NKp30 and NKp44), 2 KIRs, NKG2D and CD94. These
observations indicate that the NK cells that develop in the
BALB/c Rag2
2/2/cc
2/2 mice are similar to those that develop
naturally in humans as they express many common human NK cell
markers and also behave normally by producing human IFN-c in
response to stimulation with human IL-15 as well as the classic NK-
cell activator polyI:C.
The expression of CD94 and KIRs on human NK cells is
important as interactionsbetween theseinhibitoryreceptorsandself
MHC class I molecules prevent killing of ‘self’ cells, whereas lack of
MHC class I expression on a cell induces an NK cell response
[36–38]. In addition, NK cell inhibitory receptors mayplay a role in
the acquisition of functionality during NK cell development.
‘Licensing’ of NK cells is thought to involve interactions between
inhibitory receptors (such as CD94, NKG2A/B/C and KIRs) and
MHC class I ligands which allow NK cells to become fully
functional. If this interaction does not occur, as observed in MHC
class I-deficient mice, NK cells become hyporesponsive even when
stimulated through activating receptors [39–41]. Unlicensed NK
cells may still have the capacity to become functional if they are
sufficiently stimulated by polyI:C, cytokines or inflammation
[40,42]. In the BALB/c Rag2
2/2/cc
2/2 model, human NK cells
areable to kill K562 target cells without prior stimulationsuggesting
that some form of ‘licensing’ has occurred. It is possible that human
NK cell receptors may have some cross-reactivity with murine
MHC class I molecules or that NK cells may be licensed by other
developing human cells expressing MHC class I. It is also possible
that unlicensed human NK cells become activated by cytokines
present in the murine microenvironment.
There is a growing body of evidence that supports a role for NK
cells in anti-tumor immunity. Much of this evidence comes from
studies using mouse models in which NK cells have been depleted
or strains that are deficient in NK cell development [27,43,44].
The role of NKT cells in anti-tumor responses is less clear
however, there is evidence that they participate in tumor
immunosurveillance and exert anti-tumor responses [24,45–48].
In humans, in vivo evidence of NK/NKT-mediated tumor
inhibition is lacking due to the ethical and practical restrictions
on using human subjects and the absence of a clinically relevant
model. In the present study, we have shown that NK cells from
reconstituted BALB/cRag2
2/2/cc
2/2 mice could inhibit the
Figure 7. Survival and body weight after K562 challenge. (A)
Mice were challenged i.v. with K562 cells and monitored for survival.
(n=9 reconstituted mice, n=6 non-reconstituted mice). (B) After K562
challenge, mice were also monitored daily for changes in body weight
(n=5).
doi:10.1371/journal.pone.0008379.g007
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reconstituted mice. In addition, NK cells were able to kill K562
cells as well as produce IFN-c in response to K562 stimulation in
vitro. We have also shown that reconstituted BALB/c Rag2
2/2/
cc
2/2 mice were protected against intravenous K562 tumor
challenge compared to non-reconstituted mice. Tumor burden
was much higher in non-reconstituted than in reconstituted mice
examined at the same time point after K562 cell injection. This
may be explained, in part, by the observation that spleen cells from
reconstituted, K562-challenged mice produced more human IFN-
c than cells from reconstituted, non-challenged mice. Finally, the
reconstituted mice that survived had no detectable K562 cells in
any organs upon termination of the experiment at 90 days post
tumor injection indicating that they completely cleared the tumor
cells (Figure S2). To further support the role of NK/T cells in the
anti-K562 response, reconstituted mice were depleted of CD56
+
cells and challenged with K562 cells. The CD56-depleted mice did
not survive the challenge and reached endpoint at the same time
as the control, non-reconstituted mice. It is thus apparent that
human NK/T cells which have developed in reconstituted mice
have potent anti-tumor effects in vivo.
This humanized mouse model has many potential applications
in the field of tumor immunity and therapy. It is an appropriate
model in which to study innate immune surveillance of human
tumor cells and the methods by which human immune cells
naturally detect and control tumor growth. In addition, it is a
Figure 8. Tumour burden and IFN-c production in K562-challenged Rag2
2/2/cc
2/2 mice. Reconstituted and non-reconstituted mice were
challenged i.v. with K562 cells. Various organs were removed from mice after 40 days and stained for glyA expressed by K562 cells. (A) Representative
figures showing glyA expression in different tissues. The y axis is an irrelevant channel. (B) Graph summarizing data from all mice analyzed. N=3
resonstituted mice and n=4 non-reconstituted mice.
doi:10.1371/journal.pone.0008379.g008
Human NK Cells in Mice
PLoS ONE | www.plosone.org 10 December 2009 | Volume 4 | Issue 12 | e8379clinically relevant model for examining potential NK/T cell-based
anti-tumor therapies. The K562 cells used in this study are
uniquely sensitive to NK cells and therefore may not be
representative of most human cancers. It will be important in
future studies to examine the NK cell response to more relevant
tumour challenges including primary tumour cells. With the
growing body of evidence supporting the anti-tumor effects of NK
and NKT cells, it would be beneficial to examine the effects of
exogenously administered NK activators such as IL-15 or toll-like
receptor ligands on tumor prevention and treatment. Because of
ethical concerns and restrictions regarding the use of humans in
clinical studies, humanized mice may represent the most relevant
pre-clinical model to evaluate human therapies as well as a model
in which to study basic human immune functions.
Supporting Information
Figure S1 Isotype control for Figure 3
Found at: doi:10.1371/journal.pone.0008379.s001 (1.16 MB TIF)
Figure S2 (A) Reconstituted mice that survived K562 challenge
completely cleared the tumor cells when examined 90 days after
challenge. Lightweight line represents BALB/c Rag22/2/gc2/2
mouse not injected with K562 cells. (B) Cultured K562 cells and
cells taken from solid tumors at end point were also stained for glyA.
Lightweight line represents isotype control.
Found at: doi:10.1371/journal.pone.0008379.s002 (0.45 MB TIF)
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